Rosutab-10mg

Mechanism of Action (MOA):

Rosuvastatin inhibits HMG-CoA reductase, an enzyme responsible for converting HMG-CoA to mevalonate, a precursor of cholesterol. This inhibition leads to decreased cholesterol synthesis in the liver, upregulation of LDL receptors, and increased clearance of LDL cholesterol from the bloodstream.

Dosage and Administration:

• Adults:
  • Initial dose: 5 to 10 mg once daily.
  • Maintenance dose: 5 to 40 mg once daily, depending on individual response and therapeutic goals.
• Pediatric Patients (8 years and older):
  • 5 to 20 mg once daily, based on age and clinical response.
• Administration:
  • Can be taken with or without food.
  • Swallow tablets whole with water.

Side Effects:

• Common:
  • Headache
  • Muscle pain
  • Abdominal pain
  • Nausea
  • Dizziness
• Serious:
  • Myopathy and rhabdomyolysis
  • Liver enzyme abnormalities
  • Hypersensitivity reactions

Drug Interactions:

• Increased risk of myopathy when used with gemfibrozil; concomitant use should be avoided.
• Dose adjustments may be necessary when co-administered with protease inhibitors (e.g., atazanavir, lopinavir) due to increased rosuvastatin exposure.
• Caution with concomitant use of anticoagulants; monitoring of INR is recommended.

Precautions:

• Renal Impairment: Use with caution; dose adjustments may be necessary.
• Hepatic Impairment: Contraindicated in patients with active liver disease or unexplained persistent elevations of liver transaminases.
• Pregnancy and Lactation: Contraindicated; may cause fetal harm.
• Alcohol Consumption: Limit intake due to potential liver effects.